A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
Public ClinicalTrials.gov record NCT00627419. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Single-Arm, Multicenter Study Evaluating the Safety and Antitumor Activity of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90 (HSP90), in Patients With Metastatic Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma.
Study identification
- NCT ID
- NCT00627419
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 1 participant
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2008 (Type not available)
- Primary completion
- Oct 2009 (Actual)
- Completion
- Oct 2009 (Actual)
- Last update posted
- Dec 10, 2012
2008 – 2009
United States locations
- U.S. sites
- 17
- U.S. states
- 16
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center | Tuscon | Arizona | 85724 | — |
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| University of Colorado Health Sciences Center | Aurora | Colorado | 80010 | — |
| University of Miami - Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Indiana Univ. Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Kansas Cancer Center | Kansas City | Kansas | 66160 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02021 | — |
| Mayo Comprehensive Cancer Center | Rochester | Minnesota | 55905 | — |
| Washington School of Medicine | St Louis | Missouri | 63110 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Columbia University | New York | New York | 10032 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Univ. of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Univ. of TX, MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00627419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2012 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00627419 live on ClinicalTrials.gov.